Massachusetts is home to a robust biopharmaceutical sector, where innovation thrives through research and development. This industry primarily involves the creation of therapies and diagnostics for a variety of health issues, catering to both chronic and acute conditions. With a remarkable ecosystem that includes startups, established corporations, and academic partnerships, it focuses on cutting-edge technologies such as gene therapy and biologics. As healthcare demands evolve, companies are capitalizing on precision medicine and biotech advancements to continuously improve treatment efficacy, solidifying the state’s role as a significant hub for biopharmaceutical advancements.

The companies featured in this list range from burgeoning startups to established firms, headquartered notably in Boston and Cambridge. Spanning across various therapeutic areas, these 21 companies were founded between 2003 and 2024. They possess a workforce from as few as 11 to over 1,000 employees. Their specializations include therapies for diseases like cancer, immunological disorders, and rare diseases, showcasing a blend of innovative research and clinical development.

Continue reading to discover the top biopharmaceutical companies in Massachusetts.

Top 21 Biopharmaceutical Companies Companies in Massachusetts

1. Sunovion Pharmaceuticals

• Website: sunovion.com
• Ownership type: Corporate
• Headquarters: Marlborough, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 97%, Other 3%
• Latest funding: $2.6B, September 2009
• Founded year: 2010
• Headcount: 501-1000
• LinkedIn: sunovion-pharmaceuticals-inc-

Sunovion Pharmaceuticals Inc., based in Marlborough, Massachusetts, is a biopharmaceutical company dedicated to creating innovative therapies that address critical patient needs. Founded in 2010, Sunovion focuses on drug discovery, development, and commercialization across several therapeutic areas, including psychiatry, neurology, oncology, urology, women's health, and rare diseases. The company actively engages in clinical trials to bring effective treatments to market, catering to healthcare providers and patients alike. As a subsidiary of Sumitomo Pharma Co., Ltd., Sunovion benefits from a robust global network and resources, allowing it to enhance its research and development efforts. Their commitment to improving patient outcomes through science and technology underscores their role in the biopharmaceutical industry.

2. Nimbus Therapeutics

• Website: nimbustx.com
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $210.0M, September 2023
• Founded year: 2009
• Headcount: 51-200
• LinkedIn: nimbus-therapeutics

Nimbus Therapeutics, founded in 2009 and based in Boston, Massachusetts, is a biotechnology firm dedicated to the discovery and development of small molecule therapeutics. The company specializes in addressing complex diseases, particularly in the fields of immunology, oncology, and metabolism. Utilizing a structure-based drug discovery engine, Nimbus employs cutting-edge technologies such as computational chemistry and structural biology to identify and design novel therapeutic candidates. Their approach focuses on targets that are fundamental drivers of prevalent human diseases, which have historically been challenging for other drug developers. With a workforce of approximately 110 employees, Nimbus collaborates with pharmaceutical companies and healthcare organizations to provide innovative treatment solutions. The company has recently secured $210 million in funding, reflecting strong investor interest and support for their mission to create breakthrough medicines.

3. Acceleron Pharma

• Website: acceleronpharma.com
• Ownership type: Corporate
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 94%, Canada 6%
• Latest funding: $11.5B, September 2021
• Founded year: 2003
• Headcount: 201-500
• LinkedIn: acceleron-pharma

Acceleron Pharma, founded in 2003 and based in Cambridge, Massachusetts, is a biopharmaceutical company dedicated to developing innovative therapies for serious diseases. The company specializes in treatments for hematologic and pulmonary conditions, with a focus on addressing unmet medical needs. Acceleron has made significant strides in its research and development efforts, particularly with its lead product candidates aimed at pulmonary arterial hypertension and other rare diseases. The company has received substantial funding, with a notable amount reported in 2021, which underscores investor confidence in its potential. Acceleron's commitment to advancing science and improving patient outcomes positions it as a relevant player in the biopharmaceutical industry.

4. Third Rock Ventures

• Website: thirdrockventures.com
• Ownership type: Private
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 98%, Other 2%
• Founded year: 2007
• Headcount: 51-200
• LinkedIn: third-rock-ventures

Third Rock Ventures, founded in 2007 and based in Boston, Massachusetts, is a private venture capital firm dedicated to the biotechnology and life sciences sectors. The firm is known for its strategic approach to creating and supporting companies that aim to develop transformative therapies for serious diseases. Their portfolio includes a range of companies focused on various health challenges, including autoimmune diseases, cardiometabolic conditions, and neuropsychiatric disorders. Third Rock Ventures not only invests capital but also provides operational support and strategic guidance to its portfolio companies, helping them navigate the complexities of drug development and commercialization. With a commitment to addressing unmet medical needs, Third Rock Ventures has established itself as a key player in fostering innovation within the biopharmaceutical industry.

5. Alzheon, Inc. | Preserving Future Memories

• Website: alzheon.com
• Ownership type: Venture Capital
• Headquarters: Framingham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 93%, Czech Republic 7%
• Latest funding: Series E-K, $100.0M, June 2024
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: alzheon

Alzheon, Inc. is a biotechnology firm based in Framingham, Massachusetts, founded in 2013. The company is dedicated to developing innovative therapies for Alzheimer's disease, focusing on the unmet medical needs of patients. Their lead product, valiltramiprosate (ALZ-801), is currently undergoing Phase 3 clinical trials, specifically targeting patients with the APOE4/4 genotype. This investigational treatment aims to slow disease progression and potentially prevent the onset of clinical symptoms. Alzheon has engaged in extensive research over the past decade, leading to a favorable safety profile in previous studies involving over 3,000 Alzheimer's patients. The company has also secured significant funding, including a recent $100 million investment, to support its clinical development efforts. Alzheon is committed to precision medicine, initially focusing on high-risk patients, and plans to expand its research to broader populations in the future.

6. Sanyou Biopharmaceuticals Co., Ltd.

• Website: sanyoubio.com
• Ownership type: Private Equity
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Latest funding: Series B, August 2022
• Founded year: 2015
• Headcount: 201-500
• LinkedIn: sanyou-biopharmaceuticals-co-ltd

Sanyou Biopharmaceuticals Co., Ltd. is a biopharmaceutical company based in Cambridge, Massachusetts, with additional locations in China. Established in 2015, the company specializes in the research and development of innovative biological drugs. Sanyou offers a range of services, including integrated R&D platforms, antibody development, and protein production. Their primary clientele consists of pharmaceutical companies and research institutions that seek advanced solutions for drug development. The company is actively involved in various aspects of biopharmaceutical research, including CAR-T and gene therapy antibody development. With a workforce of 201-500 employees, Sanyou is positioned to provide high-quality services and products in the biopharmaceutical sector, contributing to the advancement of drug development on a global scale.

7. Odyssey Therapeutics

• Website: odysseytx.com
• Ownership type: Private Equity
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 78%, Germany 18%, Other 4%
• Latest funding: Series C, $101.0M, December 2023
• Founded year: 2021
• Headcount: 51-200
• LinkedIn: odyssey-tx

Odyssey Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company is dedicated to discovering, developing, and commercializing precision medicines aimed at treating serious diseases, with a particular focus on immunomodulators and oncology therapies. Odyssey has developed a highly integrated drug discovery platform that combines advanced technologies to target previously difficult-to-drug areas in immunology and oncology. The company has made significant strides in its short history, advancing multiple programs into clinical and research stages. In December 2023, Odyssey announced a successful $101 million Series C funding round, bringing its total capital raised to $487 million. This funding will support the advancement of its promising pipeline and further investment in innovative drug discovery methods. Odyssey's mission is to transform patient outcomes through the efficient delivery of life-enhancing medicines.

8. Partner Therapeutics

• Website: partnertx.com
• Ownership type: Venture Capital
• Headquarters: Lexington, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 99%, Other 1%
• Latest funding: Series A, $60.0M, February 2018
• Founded year: 2017
• Headcount: 51-200
• LinkedIn: partner-therapeutics

Partner Therapeutics, founded in 2017 and based in Lexington, Massachusetts, is a biopharmaceutical company dedicated to developing and commercializing innovative therapies aimed at improving patient outcomes in cancer and other serious diseases. The company is particularly known for its product LEUKINE® (sargramostim), which is designed to address significant unmet medical needs. Partner Therapeutics actively collaborates with healthcare providers and research institutions to enhance treatment options. They have engaged in various clinical trials, including studies exploring the potential of LEUKINE in managing adverse effects associated with cancer treatments and its application in COVID-19. The company has also received $60 million in Series A funding, which supports its ongoing research and development efforts. With a workforce of approximately 188 employees, Partner Therapeutics is committed to advancing healthcare solutions and improving the lives of patients worldwide.

9. Prilenia

• Website: prilenia.com
• Ownership type: Venture Capital
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 41%, Israel 30%, Netherlands 12%, Other 16%
• Latest funding: Series B, $43.0M, November 2021
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: prilenia

Prilenia Therapeutics, founded in 2018 and based in Boston, Massachusetts, is a biotechnology company dedicated to addressing the urgent needs of patients suffering from neurodegenerative diseases. The company is focused on the clinical development of pridopidine, an investigational drug that targets the sigma-1 receptor, which plays a crucial role in neuroprotection. Pridopidine is currently undergoing late-stage clinical trials for Huntington's disease and ALS, with plans for further studies in other neurodegenerative conditions. Prilenia has received significant backing from reputable investors, raising $43 million in a Series B funding round in late 2021. The company operates globally, with a workforce distributed across the United States, Israel, the Netherlands, Germany, and Spain, reflecting its commitment to scientific excellence and patient care.

10. Cugene Inc.

• Website: cugene.com
• Ownership type: Private
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: cugene

Cugene Inc. is a biotechnology company based in Waltham, Massachusetts, founded in 2016. The company specializes in the development of precision immunology and oncology medicines, aiming to create novel therapeutic solutions for autoimmune diseases and cancer. Cugene employs advanced molecular engineering techniques to design molecules that selectively target immune cells, enhancing treatment efficacy while minimizing side effects. Their pipeline includes innovative biomedicines that leverage proprietary technology platforms to address unmet medical needs. Cugene collaborates with healthcare providers and pharmaceutical firms to advance their research and development efforts, reflecting a commitment to improving patient outcomes in challenging therapeutic areas.

11. Albireo Pharma, Inc.

• Website: albireopharma.com
• Ownership type: Corporate
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 92%, United Kingdom (UK) 8%
• Latest funding: $952.0M, January 2023
• Founded year: 2008
• Headcount: 51-200
• LinkedIn: albireopharma

Albireo Pharma, Inc. is a biopharmaceutical company based in Boston, Massachusetts, founded in 2008. The company specializes in developing innovative therapies for rare diseases, with a particular emphasis on liver conditions. Albireo's research efforts are directed towards addressing significant unmet medical needs, especially in pediatric populations. Their lead product, Bylvay (odevixibat), is designed to treat Progressive Familial Intrahepatic Cholestasis (PFIC), a rare liver disease that affects children. The company has made strides in clinical trials and has a strong pipeline of investigational therapies aimed at improving patient outcomes. In January 2023, Albireo secured $952 million in funding, underscoring its potential for growth and development in the biopharmaceutical sector.

12. HiFiBiO Therapeutics

• Website: hifibio.com
• Ownership type: Family Owned
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Founded year: 2013
• Headcount: 51-200
• LinkedIn: hifibio

HiFiBiO Therapeutics, founded in 2013 and based in Cambridge, Massachusetts, is a biotechnology company dedicated to developing innovative immunotherapies aimed at addressing high unmet medical needs. The company utilizes its proprietary Drug Intelligence Science (DIS®) platform, which combines advanced research methodologies with cutting-edge technology to improve the understanding of cellular pathology across various diseases. HiFiBiO is currently advancing several clinical programs, including multiple Phase I trials in immuno-oncology. Their approach emphasizes collaboration, as evidenced by their open innovation model and numerous partnerships with healthcare providers and pharmaceutical companies. The company has been recognized for its therapeutic innovation, being named a Fierce 15 Biotech in 2023, highlighting its potential impact in the biopharmaceutical industry.

13. Silicon Therapeutics

• Website: silicontx.com
• Ownership type: Corporate
• Headquarters: Boston, Massachusetts, United States (USA)
• Latest funding: $450.0M, February 2021
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: silicon-therapeutics

Silicon Therapeutics, founded in 2016 and based in Boston, Massachusetts, is a biopharmaceutical company dedicated to transforming drug discovery through computational methods. The company specializes in the design and optimization of small molecules, aiming to create effective therapies for various diseases. Silicon Therapeutics has garnered attention for its innovative approach, which integrates advanced computational techniques with traditional drug development processes. In February 2021, the company secured $450 million in funding, underscoring investor confidence in its potential to deliver impactful therapies. Their work is particularly relevant in the context of addressing complex diseases where traditional methods may fall short.

14. LG Chem Life Sciences USA, Inc.

• Website: innovation.lgchem.com
• Ownership type: Private
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: South Korea 60%, United States (USA) 40%
• Founded year: 2019
• Headcount: 51-200
• LinkedIn: lg-chem-life-sciences-innovation-center

LG Chem Life Sciences USA, Inc. is a biotechnology company based in Boston, Massachusetts, and is a subsidiary of LG Chem, a major South Korean chemical company. Established in 2019, the firm focuses on pharmaceuticals and innovative drug development. It is dedicated to conducting research and clinical trials to create effective treatments for serious health conditions. The company primarily serves healthcare providers and research institutions, showcasing its commitment to advancing medical science. With a pipeline that includes various drug candidates, LG Chem Life Sciences USA is actively contributing to the biopharmaceutical industry, despite not having reported any funding to date. The company employs a workforce that is split between South Korea and the United States, reflecting its international reach and collaborative approach to drug development.

15. Be Biopharma

• Website: be.bio
• Ownership type: Private
• Headquarters: Cambridge, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 98%, Cameroon 2%
• Founded year: 2020
• Headcount: 51-200
• LinkedIn: be-biopharma-inc

Be Biopharma, based in Cambridge, Massachusetts, is a private biopharmaceutical company founded in 2020. The company is dedicated to developing engineered B cell medicines aimed at treating serious diseases, with a particular focus on hemophilia B. Be Biopharma's innovative approach involves precision engineering of B cells to create therapies that can provide continuous expression of therapeutic proteins, addressing significant limitations of existing treatments. Their lead program, BE-101, is designed to modify a patient's own B cells to produce blood clotting factor IX, potentially offering a more effective and less burdensome treatment option for individuals with hemophilia B. The company is actively advancing its research and development initiatives, with a strong emphasis on improving the quality of life for patients. Be Biopharma's commitment to scientific advancement is reflected in their recent preclinical data announcements and their focus on creating a new class of cell therapies.

16. Dragonfly Therapeutics, Inc.

• Website: dragonflytx.com
• Ownership type: Venture Capital
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: March 2020
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: dragonfly-therapeutics-inc.

Dragonfly Therapeutics, Inc., founded in 2016 and based in Waltham, Massachusetts, is a biotechnology firm dedicated to creating innovative therapies that harness the immune system to combat diseases. The company specializes in drug candidates targeting autoimmune diseases, oncology, and other therapeutic areas. Dragonfly has developed two proprietary platforms, TriNKET® and CYTOKINE, which have led to a robust pipeline of over 30 drug candidates. They are currently advancing four wholly owned drugs into Phase 1b/Phase 2 clinical trials by 2025. Collaborations with prominent pharmaceutical companies such as AbbVie, Bristol-Myers Squibb, Gilead, and Merck further bolster their position in the industry. Dragonfly's mission is to revolutionize disease treatment through natural killer cell-based therapies, aiming for improved patient outcomes across various conditions.

17. Lfb Usa

• Website: lfb-usa.com
• Ownership type: Private
• Headquarters: Framingham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 98%, France 2%
• Founded year: 2014
• Headcount: 51-200
• LinkedIn: lfb-usa

Lfb Usa, established in 2014 and based in Framingham, Massachusetts, is a biopharmaceutical company dedicated to the development and manufacturing of innovative therapeutic proteins aimed at treating serious and rare diseases. The company leverages its proprietary rPRO Technology™, which enhances the production process of recombinant proteins, making it more cost-effective and scalable compared to traditional methods. Lfb Usa plays a significant role in the LFB Group, a European biopharmaceutical entity known for its expertise in biotherapies. The company is involved in various stages of product development, including clinical trials, and has successfully brought products to market, such as a recombinant form of human Factor VIIa for hemophilia treatment. Their focus on addressing unmet medical needs in areas like oncology and immunology positions them as a relevant player in the biopharmaceutical sector.

18. EMD Serono, Inc.

• Website: emdserono.com
• Ownership type: Corporate
• Headquarters: Boston, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 89%, Canada 10%
• Latest funding: $13.3B, September 2006
• Founded year: 1981
• Headcount: 1001-5000
• LinkedIn: emd-serono-inc

EMD Serono, Inc. is a biopharmaceutical company based in Boston, Massachusetts, and is part of Merck KGaA, Darmstadt, Germany. Established in 1981, EMD Serono focuses on developing innovative treatments for various medical conditions, particularly in the fields of immunology and neurology. The company is dedicated to research and development, providing investigational agents and resources for clinical trials. EMD Serono's product portfolio includes marketed products such as BAVENCIO® (avelumab) and Rebif® (interferon beta-1a), among others. The company actively engages with healthcare professionals and organizations to ensure effective treatment options are available to patients. With a workforce of approximately 1,864 employees, EMD Serono continues to contribute to advancements in biopharmaceuticals, emphasizing the importance of clinical research and patient-centered care.

19. DynamiCure Biotechnology

• Website: dynamicure.com
• Ownership type: Private
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: dynamicure

DynamiCure Biotechnology, based in Waltham, Massachusetts, is a private biopharmaceutical company founded in 2020. The firm is dedicated to drug discovery and development, particularly in the field of immunotherapy targeting cancer and autoimmune diseases. DynamiCure is advancing a pipeline of therapeutic antibody candidates, with their lead program, DC-6001, currently in a Phase 1 clinical trial. This program aims to address limitations in existing cancer treatments by targeting the CD93 pathway, which is crucial for normalizing tumor vasculature. The company collaborates with prominent academic institutions, leveraging cutting-edge research to enhance their therapeutic offerings. DynamiCure's core values emphasize empathy, dedication, collaboration, and transparency, reflecting their commitment to improving patient health and providing innovative treatment options.

20. TetraGenetics Inc.

• Website: tetragenetics.com
• Ownership type: Corporate
• Headquarters: Arlington, Massachusetts, United States (USA)
• Latest funding: September 2021
• Founded year: 2004
• Headcount: 11-50
• LinkedIn: tetragenetics-inc.

TetraGenetics Inc. is a biotechnology company based in Arlington, Massachusetts, established in 2004. The firm specializes in the discovery and development of antibody medicines, focusing on innovative therapies for various diseases, including cancer and autoimmune disorders. TetraGenetics collaborates with pharmaceutical and biotech companies to enhance drug development processes, utilizing advanced technologies to streamline the creation of effective treatments. The company has worked on numerous antibody drug programs, contributing to the advancement of therapeutic options for patients. Despite not having reported recent funding, TetraGenetics remains active in the industry, showcasing its commitment to improving patient outcomes through scientific innovation.

21. Visterra Inc.

• Website: visterrainc.com
• Ownership type: Corporate
• Headquarters: Waltham, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $430.0M, July 2018
• Founded year: 2008
• Headcount: 51-200
• LinkedIn: visterra-inc-

Visterra Inc., based in Waltham, Massachusetts, is a biotechnology company founded in 2008. The firm specializes in developing innovative therapies aimed at treating immune-mediated diseases. Visterra's research is centered around biologics, and they are currently conducting clinical trials for several investigational products, including Sibeprenlimab (VIS649), VIS171, and VIS513. Their approach integrates advanced technologies, including artificial intelligence and computational methods, to enhance the design and efficacy of their therapeutic candidates. Visterra's commitment to improving patient outcomes is evident in their focus on conditions like IgA nephropathy and dengue fever, which are often challenging to treat. With a workforce of approximately 138 employees, Visterra is part of the vibrant biopharmaceutical ecosystem in the greater Boston area, collaborating with local universities and hospitals to drive their research forward.

Biopharmaceutical Companies Insights: Key Companies in Massachusetts

Company	Headquarter	Size	Founded	Ownership
Sunovion Pharmaceuticals	Marlborough, Massachusetts, United States (USA)	501-1000	2010	Corporate
Nimbus Therapeutics	Boston, Massachusetts, United States (USA)	51-200	2009	Venture Capital
Acceleron Pharma	Cambridge, Massachusetts, United States (USA)	201-500	2003	Corporate
Third Rock Ventures	Boston, Massachusetts, United States (USA)	51-200	2007	Private
Alzheon, Inc. | Preserving Future Memories	Framingham, Massachusetts, United States (USA)	11-50	2013	Venture Capital
Sanyou Biopharmaceuticals Co., Ltd.	Cambridge, Massachusetts, United States (USA)	201-500	2015	Private Equity
Odyssey Therapeutics	Cambridge, Massachusetts, United States (USA)	51-200	2021	Private Equity
Partner Therapeutics	Lexington, Massachusetts, United States (USA)	51-200	2017	Venture Capital
Prilenia	Boston, Massachusetts, United States (USA)	11-50	2018	Venture Capital
Cugene Inc.	Waltham, Massachusetts, United States (USA)	11-50	2016	Private
Albireo Pharma, Inc.	Boston, Massachusetts, United States (USA)	51-200	2008	Corporate
HiFiBiO Therapeutics	Cambridge, Massachusetts, United States (USA)	51-200	2013	Family Owned
Silicon Therapeutics	Boston, Massachusetts, United States (USA)	51-200	2016	Corporate
LG Chem Life Sciences USA, Inc.	Boston, Massachusetts, United States (USA)	51-200	2019	Private
Be Biopharma	Cambridge, Massachusetts, United States (USA)	51-200	2020	Private
Dragonfly Therapeutics, Inc.	Waltham, Massachusetts, United States (USA)	51-200	2016	Venture Capital
Lfb Usa	Framingham, Massachusetts, United States (USA)	51-200	2014	Private
EMD Serono, Inc.	Boston, Massachusetts, United States (USA)	1001-5000	1981	Corporate
DynamiCure Biotechnology	Waltham, Massachusetts, United States (USA)	11-50	2020	Private
TetraGenetics Inc.	Arlington, Massachusetts, United States (USA)	11-50	2004	Corporate
Visterra Inc.	Waltham, Massachusetts, United States (USA)	51-200	2008	Corporate

Want to Find More Biopharmaceutical Companies Companies?

If you want to find more companies that offer innovative therapies, diagnostics, and solutions for various diseases you can do so with Inven. This list was built with Inven and there are hundreds of companies like these globally.

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!